Niraparib plus Pembrolizumab (Pembro) Versus Placebo + Pembro 1L Maintenance Therapy in Advanced NSCLC: ZEAL-1L Phase III Study

被引：0
|
作者：
Ramalingam, S. [1 ]
Arora, S. [2 ]
Neibauer, M. Whipple [2 ]
Zhou, J. [2 ]
Hazard, S. [3 ]
Frenkl, T. [2 ]
Stojadinovic, A. [2 ]
Peters, S. [4 ]
机构：
[1] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA
[2] Glaxosmithkline, Philadelphia, PA USA
[3] Glaxosmithkline, Waltham, MA USA
[4] Lausanne Univ, Oncol, Lausanne, Switzerland
来源：
JOURNAL OF THORACIC ONCOLOGY | 2021年 / 16卷 / 03期
关键词：
NSCLC; PARP inhibitor; niraparib;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P83.02
引用
收藏
页码：S653 / S654
页数：2
相关论文
共 50 条
  • [1] Niraparib (Nira) plus Pembrolizumab (Pembro) versus placebo (PBO) + Pembro 1L maintenance therapy in advanced non-small cell lung cancer (NSCLC): ZEAL-1L phase 3 study
    Schuler, M.
    Ramalingam, S.
    Arora, S.
    Neibauer, Whipple M.
    Zho, J.
    Hazard, S.
    Frenkl, T.
    Stojadinovic, A.
    Peters, S.
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 170 - 171
  • [2] Niraparib (Nira) plus Pembrolizumab (Pembro) Versus Placebo (PBO) plus Pembro first line (1L) Maintenance Therapy in Advanced Non-Small Cell Lung Cancer (NSCLC): ZEAL-1L Phase 3 Study
    Schuler, Martin
    Ramalingam, Suresh S.
    Shi, Lei
    Neibauer, Melissa Whipple
    Frenkl, Tara
    Stojadinovic, Alexander
    Peters, Solange
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 3) : 152 - 152
  • [3] First-line (1L) maintenance therapy with niraparib (nira) plus pembrolizumab (pembro) vs placebo plus pembro in advanced/metastatic non-small cell lung cancer (NSCLC): Phase III ZEAL-1L study
    Ramalingam, S. S.
    de Castro, G., Jr.
    Garassino, M. C. C.
    Mazieres, J.
    Sanborn, R. E.
    Smit, E. F. F.
    Spigel, D. R.
    Thomas, M.
    Velcheti, V.
    Zhi, E.
    Whipple Neibauer, M.
    Stojadinovic, A.
    Peters, S.
    ANNALS OF ONCOLOGY, 2021, 32 : S1030 - S1032
  • [4] First-line (1L) maintenance therapy with niraparib (nira) plus pembrolizumab (pembro) vs placebo plus pembro in advanced/metastatic non-small cell lung cancer (NSCLC): Phase 3 ZEAL-1L study
    Nagrial, Adnan
    Ramalingam, Suresh S.
    de Castro, Gilberto, Jr.
    Garassino, Marina Chiara
    Mazieres, Julien
    Sanborn, Rachel
    Smit, Egbert
    Spigel, David R.
    Thomas, Michael
    Velcheti, Vamsidhar
    Shi, Lei
    Neibauer, Melissa Whipple
    Stojadinovic, Alexander
    Peters, Solange
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2021, 17 : 204 - 205
  • [5] Analysis of PFS2 by subsequent therapy in KEYNOTE-361: Pembrolizumab (pembro) plus chemotherapy (chemo) or pembro alone versus chemo as 1L therapy for advanced urothelial carcinoma (UC).
    Ozguroglu, Mustafa
    Alva, Ajjai Shivaram
    Csoszi, Tibor
    Matsubara, Nobuaki
    Geczi, Lajos
    Cheng, Susanna Y.
    Fradet, Yves
    Oudard, Stephane
    Vulsteke, Christof
    Morales-Barrera, Rafael
    Flechon, Aude
    Gunduz, Seyda
    Loriot, Yohann
    Rodriguez-Vida, Alejo
    Mamtani, Ronac
    Yu, Evan Y.
    Nam, Kijoeng
    Imai, Kentaro
    Moreno, Blanca Homet
    Powles, Thomas
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
  • [6] Phase III LEAP-006 safety run-in (Part 1): 1L pembrolizumab (Pembro) plus chemotherapy (Chemo) with lenvatinib (Len) for metastatic NSCLC
    Nishio, M.
    Peled, N.
    Zer, A.
    Houghton, B.
    Bar, J.
    Drew, D.
    Herbst, R.
    Rodriguez-Abreu, D.
    Talpur, R.
    Golden, L.
    Yin, L.
    Dang, T.
    Hui, R.
    ANNALS OF ONCOLOGY, 2020, 31 : S848 - S849
  • [7] Randomized, placebo-controlled phase III study of 1L pembrolizumab (Pembro) plus carboplatin/taxane followed by pembro with or without maintenance olaparib in patients (Pts) with metastatic squamous non-small cell lung cancer (sqNSCLC): KEYLYNK-008
    Gray, J. E.
    Owonikoko, T. K.
    Kato, T.
    Nadal, E.
    Greystoke, A.
    Cardona, A. F.
    Penrod, J.
    Wei, Z.
    Lara-Guerra, H.
    Schulz, C.
    ANNALS OF ONCOLOGY, 2020, 31 : S896 - S896
  • [8] Real-world evaluation of first-line (1L) pembrolizumab (pembro) monotherapy for PD-L1-positive (TPS ≥50%), advanced NSCLC in Japan
    Goto, Y.
    Santorelli, M. L.
    Taniguchi, K.
    Kamitani, T.
    Irisawa, M.
    Kanda, K.
    Abe, M.
    Burke, T.
    Nokihara, H.
    ANNALS OF ONCOLOGY, 2021, 32 : S1008 - S1009
  • [9] Health-related quality of life for pembrolizumab (pembro) plus ipilimumab (ipi) versus pembro plus placebo in patients with metastatic NSCLC with PD-L1 tumor proportion score ≥ 50%: KEYNOTE-598.
    Sendur, Mehmet Nahit
    Reck, Martin
    Rodriguez-Abreu, Delvys
    Park, Keunchil
    Lee, Dae Ho
    Cicin, Irfan
    Yumuk, Perran Fulden
    Orlandi, Francisco J.
    Leal, Ticiana A.
    Molinier, Olivier
    Soparattanapaisarn, Nopadol
    Langleben, Adrian
    Califano, Raffaele
    Medgyasszay, Balazs
    Hsia, Te-Chun
    Otterson, Gregory Alan
    Xu, Lu
    Burke, Thomas A.
    Samkari, Ayman
    Boyer, Michael J.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [10] Pembrolizumab Plus Ipilimumab vs Pembrolizumab Plus Placebo as 1L Therapy for Metastatic NSCLC of PD-L1 TPS ≥50%: KEYNOTE-598
    Boyer, M.
    Sendur, M. A. N.
    Rodriguez-Abreu, D.
    Park, K.
    Lee, D. H.
    Cicin, I.
    Yumuk, P. F.
    Orlandi, F.
    Leal, T.
    Molinier, O.
    Soparattanapaisam, N.
    Langleben, A.
    Califano, R.
    Medgyasszay, B.
    Hsia, T.
    Otterson, G.
    Xu, L.
    Piperdi, B.
    Samkari, A.
    Reck, M.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S61 - S62
12345